Lack of pantoprazole drug interactions in man: An updated review

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue SUPPL. 1, 1996, Pages

  Steinijans, V W ^a   Huber, R ^a   Hartmann, M ^a   Zech, K ^a   Bliesath, H ^a   Wurst, W ^a   Radtke, H W ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

Antipyrine; Caffeine; Carbamazepine; Cytochrome P450; Diazepam; Diclofenac; Digoxin; Drug interaction; Ethanol; Glibenclamide; Hormonal contraceptive; Metoprolol; Nifedipine; Pantoprazole; Phenprocoumon; Phenytoin; Theophylline; Warfarin

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ALCOHOL; CAFFEINE; CARBAMAZEPINE; CIMETIDINE; CONTRACEPTIVE AGENT; CYTOCHROME; DIAZEPAM; DICLOFENAC; DIGOXIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GLIBENCLAMIDE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; METOPROLOL; NIFEDIPINE; OMEPRAZOLE; PANTOPRAZOLE; PHENAZONE; PHENPROCOUMON; PHENYTOIN; PROTON PUMP INHIBITOR; RANITIDINE; SACCHARIC ACID; THEOPHYLLINE; WARFARIN;

ARTICLE; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG INTERACTION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; META ANALYSIS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; STOMACH PH; URINARY EXCRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; BENZIMIDAZOLES; DRUG INTERACTIONS; ENZYME INHIBITORS; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; OMEPRAZOLE; SULFOXIDES;

EID: 0029897653     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (124)

1. Ahmad S 1991 Omeprazole-warfarin interaction. South Med J 84: 674-675
2. Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P 1990a Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 39: 51-54
3. Andersson T, Lagerström PO, Unge P 1990b A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit 12: 329-333
4. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L 1990c Slow omeprazole metabolisers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12: 415-416
5. Andersson T 1991 Omeprazole Drug Interaction Studies. Clin Pharmacokinet 21: 195-212
6. Andersson T, Bergstrand R, Cederberg C, Eriksson S, Lagerström PO, Skånberg I 1991 Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 101: 943-947
7. Andersson T, Miners JO, Veronese ME, Tassaneeyakul Wi, Tassaneeyakul Wo, Meyer UA, Birkett DJ 1993 Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36: 521-530
8. Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L 1993 Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker for CYP2C activity. Br J Clin Pharmacol 36: 380-382
9. Barnes PJ, Pauwels RA 1994 Theophylline in the management of asthma: time for reappraisal? Eur Resp J 7: 579-591
10. Benet LZ, Zech K 1994 Pharmacokinetics -a relevant factor for the choice of a drug? Aliment Pharmacol Ther 8 (Suppl. 1): 25-32
11. Bergendal L, Friberg A, Schaffrath A 1995 Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci 17: 152-157
12. Bergstrand R, Grind M, Nyberg G, Olofsson B 1995 Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin Drug Invest 9: 67-71
13. Bertilson L, Höjer B, Tybring G, Osterloh J, Rane A 1980 Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther 27: 83-88
14. +-ATPase inhibitor pantoprazole after single intravenous administration. Int J Clin Pharmacol Ther 32: 44-50
15. Bliesath H, Huber R, Steinijans VW, Koch HJ, Kunz K, Wurst W 1996a Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int J Clin Pharmacol Ther 34: 51-55
16. Bliesath H, Huber R, Steinijans VW, Koch H, Wurst W, Mascher H 1996b Lack of pharmacokinetic interaction between pantoprazole and diclofenac. Int J Clin Pharmacol Ther 34: 152-156
17. Blom S 1963 Tic douloureux treated with new anticonvulsant: Experiences with G32883. Arch Neurol 9: 285-290
18. Blume H, Walter-Sack I, Ali S, Siewert M, Stenzhorn G, Novak N, Weber E 1987 Untersuchung zur therapeutischen Relevanz der Bioäquivalenz und zur Chargenhomogenität glibenclamidhaltiger Fertigarzneimittel. Pharm Ztg 132: 2352-2362
19. Breckenridge AM, Orme M, Wesseling H, Lewis RJ, Gibbons R 1974 Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 15: 424-430
20. Breimer DD, Schellens JHM 1990 A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans. TiPS 11: 223-225
21. Brunner G, Chang J, Hartmann M, Huber R, Bliesath H, Lühmann R, Wurst W 1994 Pharmakokinetik von Pantoprazol bei Patienten mit Leberzirrhose. Med Klin 89 (Suppl. I): 189
22. Caballería C, Frezza M, Hernández-Munoz R, et al. 1989 Gastric origin of the first-pass metabolism of ethanol in humans: effect of gastrectomy. Gastroenterol 97: 1205-1209
23. Campbell ME, Grant DM, Inaba T, Kalow W 1987 Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon - inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 15: 237-249
24. Cohen AF, Kroon R, Schoemaker R, Hoogkamer H, van Vliet A 1991 Influence of gastric acidity on the bioavailability of digoxin. Am Intern Med 115: 540-545
25. Cohen AF, Kroon R, Schoemaker R, Breimer DD, van Vliet-Verbeek A, Brandenburg HC 1993 The bioavailability of digoxin from three oral formulations measured by specific h.p.l.c. assay. Br J Clin Pharmacol 35: 136-142
26. Colin-Jones DC 1993 Safety of lansoprazole. Aliment Pharmacol Ther 7 (Suppl. I): 56-60
27. Conney AH, Pantuck EJ, Hsiao KC, Garland WA, Anderson KE, Alvares AP, Kappas A 1976 Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmcol Ther 20: 633-642
28. CPMP (Committee for Proprietary Medicinal Products) Working Party on the Efficacy of Medicinal Products 1991 Note for guidance: Investigation of bioavailability and bioequivalence.
29. De la Rey N, Schall R, Luus HG, Meyer BH, Müller FO 1993 Assessing the risk of ovulation in interaction studies of drugs and oral contraceptives. Int J Clin Pharmacol Ther Toxicol 31: 435-439
30. Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoit M, Flouvat B 1991 The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 16: 315-320
31. Delhotal-Landes B, Petite JP, Flouvat B 1995 Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 28: 458-470
32. DeMey C, Meineke I, Steinijans VW, Huber R, Hartmann M, Bliesath H, Wurst W 1994 Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther 32: 98-106
33. Diletti E, Hauschke D, Steinijans VW 1991 Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29: 1-8
34. Di Padova C, Worner TM, Julkunen RJ, Lieber CS 1987 Effects of fasting and chronic alcohol consumption on the first-pass metabolism of ethanol. Gastroenterology 92: 1169-1173
35. Duursema L, Müller FO, Hundt HKL, Heyns A du P, Meyer BH , Luus HG 1992 Model to detect warfarin-drug interactions in man. Drug Invest 4: 395-402
36. Duursema L, Müller FO, Schall R, Middle MV, Hundt HKL, Groenewoud G, Steinijans VW, Bliesath H 1995 Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 39: 700-703
37. Ehrlich A, Fuder H, Hartmann M, Wieckhorst G, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W, Lücker PW 1996 Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Eur J Clin Pharmacol: 51 (in press)
38. Eichelbaum M, Tomson T, Tybring G, Bertilson L 1985 Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokin 10: 80-90
39. Faigle JW, Feldman KF 1982 Carbamazepine biotransformation.In Woodbury et al. (eds) Antiepileptic drugs, 2nd edn. pp 483-495 Raven Press, NY
40. Fazio A 1991 Oral contraceptive drug interactions: Important considerations. Southern Med J 84: 997-1002
41. Food and Drug Administration (FDA) 1992 Guidance on statistical procedures for bioequivalence studies using standard two-treatment cross-over design. Informal communication by the Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evalutation and Research, Food and Drug Administration, Rockville, MD
42. Fitton A, Wiseman L 1996 Pantoprazole - a review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 51: 460-482
43. Forth W, Henschler D, Rummel W (eds) 1992 Allgemeine und spezielle Pharmakologie und Toxikologie, BI Wissenschaftsverlag Mannheim/Wien/Zürich, 6th edn
44. Fuchs W, Sennewald R, Klotz U 1994 Lansoprazole does not affect the bioavailability of oral contraceptives. Br J Clin Pharmacol 38: 376-380
45. García B, Lacambra C, Garrote F, García-Plaza I, Solis J 1994 Possible potentiation of anticoagulant effect of acenocoumarol by omeprazole. Pharm World Sci 16: 231-232
46. Gault H, Kalra J, Ahmed M, Kepkay D, Barrowman J 1980 Influence of gastric pH on digoxin biotransformation. I. Intragastric hydrolysis. Clin Pharmacol Ther 27: 16-21
47. Granneman GR, Karol MD, Locke CS, Cavanaugh JH 1995 Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit 17: 460-464
48. Gugler R, Jensen JC 1985 Omeprazole inhibits oxidative drug metabolism. Gastroenterol 89: 1235-1241
49. Gugler R, Jensen JC 1987 Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther 33: 133-137
50. Gugler R, Hartmann M, Rudi J, Brod I, Huber R, Steinijans VW, Bliesath H, Wurst W, Klotz U 1996 Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol 41: (in press)
51. +-ATPase inhibitor pantoprazole. Gastroenterol. 106 (Suppl.): A91
52. Hartmann M, Huber R, Bliesath H, Steinijans VW, Koch HJ, Wurst W, Kunz K 1995a Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Int J Clin Pharmacol Ther 33: 481-485
53. Hartmann M, Bliesath H, Zech K, Koch H, Steinijans VW, Wurst W, Mascher H 1995b Pantoprazole does not influence CYP1A2 activity in man. Gastroenterol 108 (Suppl): A109
54. Heinemeyer G, Roots I, Lestau P, Klaiber HR, Dennhardt R 1986 D-glucaric acid excretion in critical care patients - comparison with 6β-hydroxycortisol excretion and serum γ-glutamyltranspeptidase activity and relation to multiple drug therapy. Br J Clin Pharmacol 21: 9-18
55. +- ATPase inhibitor BY1023/SK&F96022 and its sulphone metabolite in serum or plasma by direct injection and fully automated precolumn sample clean up. J Chromatog 529: 389-401
56. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E 1995 Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 9: 363-378
57. Huber R, Hartmann M, Bliesath H, Lühmann R, Steinijans VW, Zech K 1996a Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 34:185-194
58. Huber R, Bliesath H, Hartmann M, Koch HJ, Steinijans VW, Mascher H, Wurst W 1996b Pantoprazole does not influence the pharmacokinetics of carbamazepine. Gastroenterol (in press)
59. Judmaier G, Koelz HR and Pantoprazole-Duodenal Ulcer-Study Group 1994 Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Aliment Pharmacol Ther 8: 81-86
60. Julkunen R, Tannenbaum L, Baraona E et al. 1985 First pass metabolism of ethanol: an important determinant of blood levels after alcohol consumption. Alcohol 2: 437-441
61. Kano H, Okuno H, Takasu M, Takeda K, Shiozaki Y, Inoue K 1992 Inhibition and induction of liver drug metabolizing activity by omeprazole. Hel J Gastroenterol 5: 150
62. Kalow W, Tang BK 1991 Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidate activities. Clin Pharmacol Ther 50: 508-519.
63. Kalow W, Tang BK 1993 The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 53: 503-514
64. Kokufu T, Ihara N, Sugioka N, Koyama H, Ohta T, Mori S, Nakajima K 1995 Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 48: 391-395
65. Koch HJ, Hartmann M, Bliesath H, Huber R, Steinijans VW, Mascher H, Wurst W 1996 Pantoprazole does not influence metoprolol pharmacokinetics and pharmacodynamics in man. Gastroenterol (in press)
66. Lamboeuf Y, de Saint-Blanquat G, Derache R 1981 Mucosal alcohol dehydrogenase- and aldehyde dehydrogenase-mediated ethanol oxidation in the digestive tract of the rat. Biochem Pharmacol 30: 542-545
67. Lamboeuf Y, la Droitte P, de Saint-Blanquat G 1983 The gastro-intestinal metabolism of ethanol in the rat: effect of chronic alcoholic intoxication. Arch Int Pharmacodyn Ther 261: 157-169
68. Leemann T, Transon C, Dayer P 1993 Cytochrome P450TB (CYP2C): a major monooxygenase catalysing diclofenac 4′-hydroxylation in human liver. Life Sci 52: 24-29
69. Lefebvre RA, Flouvat B, Karolac-Tamisier S, Moerman E, Van Ganse E 1992 Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 52: 458-463
70. Lin GW, Leste D 1980 Significance of the gastrointestinal tract in the in vivo metabolism of ethanol in the rat. Adv Exp Med Biol 132: 281-186
71. Martindale W 1996 The extra pharmacopoeia, 31st edition, ed Reynolds JEF, London: The Pharmaceutical Press
72. Melander A, Bitzén PO, Faber O, Group L 1989 Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use. Drug 37: 58-72
73. Middle MV, Müller FO, Schall R, Hundt HKL, Mogilnicka EM, Beneke PC 1995a Effect of pantoprazole on ovulation suppression by a low-dose hormonal contraceptive. Clin Drug Invest 9: 54-56
74. Middle MV, Müller FO, Schall R, Groenewoud G, Hundt HKL, Huber R, Bliesath H, Steinijans VW 1995b No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther 33: 304-307
75. Mohamed AH, Hunt RH 1994 The rationale of acid suppression in the treatment of acid-related disease. Aliment Pharmacol Ther 8 (Suppl.1): 3-10
76. Müller P, Simon B, Khalil H, Lühmann R, Leucht U, Schneider A 1992 Dose range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients. Z Gastroenterol 30: 771-775
77. Murad F, Kuret JA 1990 Estrogens and progestins. In: The pharmacological basis of therapeutics. Gilman, Rall, Nies, Taylor (Eds), New York, USA. Pergamon Press 1402-1409
78. Naidu MUR, Shobha JC, Dixit VK, Kumar A, Kumar TR, Sekhar KR, Sekhar EC 1994 Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Invest 7: 8-12
79. Neugebauer G, Betzien G, Hrstka V, Kaufmann B, v. Möllendorff E, Abshagen U 1985 Absolute unavailability and bioequivalence of glibenclamide (Semi-Euglucon® N). Int J Clin Pharmacol Ther Toxicol 23: 453-460
80. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Siverman BW 1995 Caffeine as a metabolic probe: a comparison of the metabolic ratios used to access CYP1A2 activity. Br J Clin Pharmacol 39: 65-69
81. Oosterhuis B, Jonkman JHG, Andersson T, Zuiderwijk PBM, Jedema JN 1991 Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 32: 569-572
82. O'Reilly RA 1974 Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 16: 348-354
83. Parkinson A, Hurwitz A 1991 Omeprazole and the induction of human cytochrome P-450: a response to concerns about potential adverse effects. Gastroenterol 100: 1157-1164
84. Pearson JG, Antal EJ, Raehl CL, Gorsch HK, Craig WA, Alberts KS, Welling PG 1986 Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther 39: 18-24
85. Peart GF, Boutagy J, Shenfield GM 1987 Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. Eur J Clin Pharmacol 33: 397-402
86. Peeters PAM, Oosterhuis B, Zech K, Huber R, Hartmann M, Jonkman JHG 1993 Pantoprazole pharmacokinetics and metabolism after oral and intravenous administration of 14C-labelled pantoprazole to young healthy male volunteers. Pharm World Sci 15 (Suppl. L): L7
87. Petersen KU 1995 Review article: omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther 9: 1-9
88. Pippenger CE 1987 Clinically significant carbamazepine drug interactions: an overview. Epilepsia 18: S71-S76.
89. Plosker GL, Clissold SP 1992 Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and ischemic heart disease. Drugs 43: 382-414
90. Prichard PJ, Walt RP, Kitchingman GK, Somerville KW, Longman MJS, Williams J, Richens A 1987 Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 24: 543-545
91. Reill L, Erhardt F, Fischer R, Rost KL, Roots I, Londong W 1993 Effect of oral pantoprazole on 24-h intragastric pH, serum gastrin profile and drug metabolizing enzyme activity in man - a placebo-controlled comparison with ranitidine. Gut 34(Suppl.) : 63
92. Robson RA, Miners JO, Matthews AP, Stupans I, Meller D, McManus ME, Birkett DJ 1988 Characterization of theophylline metabolism by human liver microsomes. Biochem Pharmacol 37: 1651-1659
93. Rost KL, Brösicke H, Brockmöller J, Scheffler M, Helge H, Roots I 1992 Increase of cytochrome P4501A2 activity by omeprazole: evidence by the 13C-(N-3-methyl)-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 52: 170-180
94. Roux A, Naline E, Molinier P, Dellatolas F, Lemaire M, Flouvat B 1993 Effect of lansoprazole and omeprazole on the metabolism of theophylline and antipyrine in man. Eur J Drug Metab Pharmacokin 18: 125
95. Sauter R, Steinijans VW, Diletti E, Böhm A, Schulz H-U 1992 Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 30: 233-256
96. Schepp W, Rehner M, Witzel L 1994 A review of treatment of duodenal and gastric ulcers -pantoprazole vs. omeprazole. Aliment Pharmacol Ther 8 (Suppl. 1): 53-57
97. Schulz H-U, Hartmann M, Steinijans VW, Huber R, Lührmann B, Bliesath H, Wurst W 1991 Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol 29: 369-375
98. Shader RI 1993 I recently saw a patient taking omeprazole for a duodenal ulcer who was wobbly and sedated by the small doses of diazepam that he had previously tolerated. How is this explained? J Clin Psychopharmacol 13: 459
99. Shin JM, Besancon M, Prinz C, Simon A, Sachs G 1994 Continuing development of acid pump inhibitors: site of action of pantoprazole. Aliment Pharmacol Ther 8 (Suppl. 1): 11-23
100. +-ATPase inhibitor BY1023/SK&F96022 - inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4: 239-245
101. +-ATPase inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers. Z Gastroenterol 9: 443-447
102. Simon B, Müller P, Marinis E, Lühmann R, Huber R, Hartmann M, Wurst W 1990c Effect of repeated oral administration of BY 1023/SK&F96022 - a new substituted benzimidazole derivative - on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4: 373-379
103. +-ATPase inhibitor. Biochem Pharmacol 39: 1799-1806
104. Simon WA 1995 Pantoprazole -which cytochrome P450 isozymes are involved in its biotransformation? Gut 37(Suppl. 2): A1177
105. Skaunic V, Hulek P, Martinkova J 1978 Changes in kinetics of exogenous dyes in the ageing process. In: Kitani (ed) Liver and ageing, pp. 115-130, Elsevier North-Holland, Amsterdam
106. Sommerville K, Faulkner G, Longman M 1986 Non-steroidal antiinflammatory drugs and bleeding peptic ulcer. Lancet i: 489-492
107. Soons PA, van den Berg G, Danhof M, van Brummelen P, Jansen JB, Lamers CB, Breimer DD 1992 Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol 42: 319-324
108. Steinijans VW, Hartmann M, Huber R, Radtke HW 1991 Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 29: 323-328
109. Steinijans VW, Sauter R 1993 Food studies: acceptance criteria and statistics. In: Midha KK, Blume HH (eds) Bio-International: bioavailability, bioequivalence and pharmacokinetics. International conference of F.I.P. "Bio-International '92", Bad Homburg, Germany; Medpharm Scientific Publishers, Stuttgart, pp. 235-250
110. Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW 1994 Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther 32: 385-399
111. Sutfin T, Balmer K, Boström H, Eriksson S, Höglund P, Paulsen O 1989 Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 11: 176-184
112. Tang-Liu DD, Williams RL, Riegelman S 1982 Nonlinear theophylline elimination. Clin Pharmacol Ther 31: 358-369
113. Teyssen S, Singer MV, Heinze H, Schneider A, Fischer R 1996 Pantoprazole does not influence the pharmacokinetics of ethanol in healthy volunteers. Gastroenterol (in press)
114. Todd PA, Sorkin EM 1988 Diclofenac sodium reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 35: 244-285
115. Toon S, Hopkins KJ, Gastang FM, Diquet B, Gill TS, Rowland M 1986 The warfarin-cimetidine interaction: stereochemical considerations. Br J Clin Pharmacol 21: 245-246
116. Tucker GT 1992 The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30: 550-553
117. Tucker GT 1994 The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 8 (Suppl. 1): 33-38
118. Unge P, Svedberg LE, Nordgren A, Blom H, Andersson T, Lagerstroem PO, Idstroem JP 1992 A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 34: 509-512
119. Upton RA, Thiercelin JF, Guentert TW, Wallace SM, Powell JR, Sansom L, Riegelman S 1982 Intraindividual variability in theophylline pharmacokinetics: Statistical verification in 39 of 60 healthy young adults. J Pharmacokinet Biopharm 10: 123-134
120. Vistisen K, Loft S, Poulsen HE 1990 Cytochrome P4501A2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise. In: C. M. Witmer et al. (eds) Biol. Reactive Intermediates IV, pp. 407-410, Plenum Press, New York.
121. Wagner JG 1986 Lack of first-pass metabolism of ethanol at blood concentrations in the social drinking range. Life Sci 39: 407-414
122. Walter-Sack I, Bliesath H, Stötzer F, Huber R, Steinijans VW, Mascher H 1996 No pharmacokinetic and pharmacodynamic interaction between pantoprazole and glibenclamide. Gut (in press)
123. Ward AJM, McKenniff M, Evans JM, Page CP, Costello JF 1993 Theophylline - an immunomodulatory role in asthma ? Am Rev Respir Dis 147: 518-523
124. Wynne HA, Goudevenos J, Rawlins MD, James OFW, Adams PC, Woodhouse KW 1990 Hepatic drug clearance: the effect of age using indocyanine green as a model compound. Br J Clin Pharmacol 30: 634-637